Drawing for EMOTE

USPTO serial 87189973

EMOTE

Reviewed by CopyMark Law Group

Reg. 5199418Status 702Renewal
Filing date
Status date
Registration date
May 9, 2017
Examiner
BELL, MARLENE D
Law office
TMO LAW OFFICE 118

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with EMOTE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Emily A. Bayton

Emily A. Bayton FAEGRE DRINKER BIDDLE & REATH LLP1144 15th Street, Suite 3400Denver, CO 80202UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
010Medical Apparatus, namely, Electrolarynx Speech AidACTIVESep 29, 2016

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 9, 2026REM2COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED—
Oct 31, 2023NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Oct 31, 2023C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Oct 31, 2023APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
May 3, 2023E815TEAS SECTION 8 & 15 RECEIVED—
Apr 19, 2023ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Dec 15, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Dec 15, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 15, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Dec 15, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 15, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 15, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Sep 21, 2022ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
May 9, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 23, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 23, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 9, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 21, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 21, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 1, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 17, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 9, 2017DOCKASSIGNED TO EXAMINER—
Oct 6, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 4, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance